A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
暂无分享,去创建一个
P. Thall | E. Jonasch | C. Wood | C. Ng | A. Siefker-Radtke | L. Pagliaro | Xuemei Wang | N. Tannir | P. Mathew | L. Wooten